Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue
Total revenue	$ 4,306,031	$ 4,214,441
Operating expenses
Research and development, net	10,910,679	9,964,720
General and administrative	9,935,963	8,801,661
Sales and marketing	3,713,263	3,094,092
Transaction costs		471,522
Impairment of right-of-use asset	170,714	101,838
Impairment of intangible assets		750,596
Gain on sale of equipment		(100,000)
Total operating expenses	27,579,067	26,932,920
Operating loss	(23,273,036)	(22,718,479)
Other expense
Gain on extinguishment of debt	259,353	884,970
Warrant inducement expense	(7,755,541)
Interest and other income, net	45,179	105,627
Interest expense	(4,799,331)	(3,399,384)
Foreign currency transaction gains/(losses)	891,223	(1,468,855)
Change in fair value of derivative financial instruments	(129,731)	517,680
Total other expense	(11,488,848)	(3,359,962)
Loss before income taxes	(34,761,884)	(26,078,441)
Provision for income taxes	43,828	132,403
Net loss	(34,805,712)	(26,210,844)
Deemed dividend on beneficial conversion feature	(7,166,752)
Net loss available to common stockholders	$ (41,972,464)	$ (26,210,844)
Basic and diluted net loss per share attributable to common stockholders	$ (1.14)	$ (1.66)
Weighted average shares outstanding - basic and diluted	36,674,083	15,800,781
Net loss	$ (34,805,712)	$ (26,210,844)
Other comprehensive (loss) income - foreign currency translation	(1,961,556)	2,564,497
Comprehensive loss	(36,767,268)	(23,646,347)
Product sales [Member]
Revenue
Total revenue	2,656,669	2,704,364
Operating expenses
Cost of products and services	2,295,828	3,360,280
Laboratory services [Member]
Revenue
Total revenue	813,210	167,736
Operating expenses
Cost of products and services	552,620	488,211
Collaborations Revenue [Member]
Revenue
Total revenue	$ 836,152	$ 1,342,341